Objective: To develop an algorithm for the evaluation of real world walking in Parkinson’s disease and other disorders, using data obtained from a lower back-worn device.

Background: Efforts to mitigate the loss of mobility in Parkinson’s disease (PD) are an increasing priority and promising interventions to investigate this aspect are now under investigation. To target mobility loss effectively and to be able to prevent it, validated tools that can detect and measure it in daily life are needed. Digital technologies have the potential for measuring and monitoring digital mobility outcomes in real life, but to date, no robust and well-validated solutions for the assessment of mobility in PD patients are available.

Method: The overarching aims of Mobilise-D (“Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement”) are to: 1) provide a valid solution for real-life digital mobility assessment; 2) validate digital mobility outcomes in predicting clinical outcome in a variety of disease states including PD, chronic obstructive pulmonary disease, multiple sclerosis, and proximal femoral fracture; and 3) obtain regulatory and health stakeholder approval for mobility assessment parameters derived from digital, wearable technology.

Results: Mobilise-D is a 50 million Euro project funded by the European Innovative Medicines Initiative 2 Joint Undertaking. It includes 34 partners from leading international universities and some of the world’s largest pharmaceutical and technical companies. The project began in April 2019 and will run for five years.  The focus will be on assessment of real-world walking speed and related outcomes in 5 chronic disease populations to derive a device-agnostic algorithm that can be used to predict medically relevant clinical outcomes (e.g., falls, hospitalizations, disability, death) from mobility assessment. Additional measures of mobility and disability will be collected.

Conclusion: The aim of Mobilise-D is to facilitate drug development and establish a roadmap for the clinical implementation of new, complementary tools to identify, stratify and monitor disability associated with mobility-limiting chronic diseases, including PD, with a focus on real-world walking speed. The ultimate aim is to provide open access to a cost-effective, validated assessment of mobility.

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/connecting-digital-mobility-outcomes-with-clinical-assessments-in-disorders-such-as-parkinsons-disease-the-mobilise-d-study/